Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy

Class:IdLiteratureReference:9706792
_displayNameImpact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy
_timestamp2020-11-09 09:57:12
author[Person:9706773] Kono, Miho
[Person:9706744] Fujii, Takeo
[Person:9706753] Lyons, Genevieve Ray
[Person:9706789] Huo, Lei
[Person:9706785] Bassett, Roland
[Person:9706794] Gong, Yun
[Person:9706739] Karuturi, Meghan Sri
[Person:8932053] Tripathy, Debu
[Person:9706781] Ueno, Naoto T
created[InstanceEdit:9706780] Jassal, Bijay, 2020-11-09
journalBreast Cancer Res Treat
pages101-109
pubMedIdentifier27663436
titleImpact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy
volume160
year2016
(literatureReference)[Reaction:9705926] AR binds AR agonists [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy (9706792)